An Investment in the
Future of Surgery

AxioMed CFO, Aditya Humad, on the past, present and future of total disc replacement technology

The AxioMed Freedom® Cervical and Lumbar Discs have the potential to change the paradigm of spine surgery and make a global impact in patient’s lives. Before now, the spine industry has made several attempts at providing a total disc replacement solution. These devices never achieved true adoption though, because they were designed as “ball and socket” joints – which is not how the human spine functions.

Axiomed's solution mimics the natural anatomy of a spine. The technology is comprised of a whole viscoelastic polymer core that is held between spiked titanium endplates through a proprietary locking mechanism with no keels. The technology responds to loads the way a human spine does and restores mobility for patients.

AxioMed has spent over $80 million in R&D since 2001 to finally provide the healthcare community a solution that both surgeons and patients can stand behind.

When AxioMed hit financial distress and the chance arose to acquire this revolutionary technology solution in 2014, Dr. Chin and I instantly seized the opportunity. This acquisition may prove to be one of the most significant in the history of spine. The AxioMed total disc replacement technology has been on the market in Europe for over seven years, gaining positive feedback from surgeons and patients.

We plan to raise $5 million equity in this first round to complete the lumbar disc FDA submission, start manufacturing to generate sales overseas and initiate the cervical IDE in the US.

With AxioMed now under KICVentures, we fully intend to bring this disruptive technology to market globally and believe it represents a multi-billion dollar opportunity. We believe this total disc replacement technology will change spine treatment as we know it.

Interested in Investing? Contact

AdityaHumad@kicventures.com

An Investment in the
Future of Surgery

AxioMed CFO, Aditya Humad, on the past, present and future of total disc replacement technology

The AxioMed Freedom® Cervical and Lumbar Discs have the potential to change the paradigm of spine surgery and make a global impact in patient’s lives. Before now, the spine industry has made several attempts at providing a total disc replacement solution. These devices never achieved true adoption though, because they were designed as “ball and socket” joints – which is not how the human spine functions.

Axiomed's solution mimics the natural anatomy of a spine. The technology is comprised of a whole viscoelastic polymer core that is held between spiked titanium endplates through a proprietary locking mechanism with no keels. The technology responds to loads the way a human spine does and restores mobility for patients.

AxioMed has spent over $80 million in R&D since 2001 to finally provide the healthcare community a solution that both surgeons and patients can stand behind.

When AxioMed hit financial distress and the chance arose to acquire this revolutionary technology solution in 2014, Dr. Chin and I instantly seized the opportunity. This acquisition may prove to be one of the most significant in the history of spine. The AxioMed total disc replacement technology has been on the market in Europe for over seven years, gaining positive feedback from surgeons and patients.

We plan to raise $5 million equity in this first round to complete the lumbar disc FDA submission, start manufacturing to generate sales overseas and initiate the cervical IDE in the US.

With AxioMed now under KICVentures, we fully intend to bring this disruptive technology to market globally and believe it represents a multi-billion dollar opportunity. We believe this total disc replacement technology will change spine treatment as we know it.

Interested in Investing? Contact

AdityaHumad@kicventures.com

PRIOR INVESTMENT PARTNERS

CID Equity Partners, CID Equity Partners, founded in 1981, is a leading provider of private equity and debt financing to high growth companies throughout the Mid-America region. From offices in Indianapolis, Indiana, Chicago, Illinois, and Columbus, Ohio, the firm is actively managing funds totalling nearly $400 million. Industries of interest include Information Technology, Life Sciences, Business Services and Manufacturing.

VISIT WEBSITE

Investor Growth Capital ("IGC") is publicly traded on the Stockholm exchange, and was founded in 1916 to continue the Wallenberg family´s tradition of financing and building best-in-class companies. Since its formation in the mid-1990s, IGC has continued to invest in high-quality, growth-oriented companies, primarily in the information technology and healthcare industries. IGC pursues partnerships with talented and motivated management teams offering products or services likely to produce sustainable growth.

VISIT WEBSITE

Primus Capital Funds is a Cleveland, Ohio-based venture capital firm committed to funding private companies with exceptional growth potential. Primus invests in companies at all stages of development, with a particular emphasis on growth capital financing, and has significant investment experience in business services, communications, and healthcare. Founded in 1983, Primus currently manages $625 million of private equity capital across five funds and has invested in over 100 companies since its inception.

VISIT WEBSITE

Thomas, McNerney & Partners, LLC, is a healthcare private equity firm that invests in life science and medical technology companies. The firm's partners have successfully funded companies at all stages of their development, having collectively invested over $500 million in more than 40 entities. Thomas, McNerney & Partners provides seed and early-stage funding to help entrepreneurs launch companies. Thomas, McNerney & Partners is targeting investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors.

VISIT WEBSITE

Blue Chip, is committed to helping our partners build lasting enterprises. We earn management's respect by being a creative and flexible partner who understands that time is precious and speed is essential. And we're proud to be the investor partner that management calls first when seeking advice, support or guidance.

VISIT WEBSITE

Early Stage Partners is an early stage venture capital fund based in Cleveland, Ohio. ESP was developed to fill the gap that exists in funding for early stage companies with small- to medium-size capital requirements. The company invests primarily in promising opportunities in the life sciences technology areas including software, supply chain management and advanced manufacturing, and polymers and advanced materials.

VISIT WEBSITE

MB Venture Partners is a Memphis, Tennessee venture capital firm that provides venture capital and strategic direction to life sciences companies. The Firm invests in medical device and biotech companies at various stages of development and is especially interested in product solutions for musculoskeletal disease. MB Venture Partners currently manages two funds totaling $76 million under management.

VISIT WEBSITE

Reservoir Venture Partners, a venture capital firm located in Columbus, Ohio, brings capital, business-building acumen, and a strong network to entrepreneurs and their teams. Reservoir targets investments in seed and early-stage technology-focused companies with an emphasis on biosciences and information technology. The firm focuses on investments in Ohio and throughout the Midwest.

VISIT WEBSITE

Charter Oak Equity, and its predecessor funds have invested in private equity since 1992. We focus on niche manufacturing, packaging, medical products & services, specialty chemicals, consumer products and financial services companies ranging in size from start up to $150 million enterprise value. To date, over $500 million in control-oriented capital has been invested in 27 portfolio companies through over 50 acquisitions.

VISIT WEBSITE

For US:

Freedom® Lumbar Disc is an investigational device, limited by federal/or United States law to investigational use. Freedom® Cervical Disc not available in the US.